Factor Xa, a trypsin-like serine protease that catalyzes the conversion of prothrombin to thrombin, is located at the crucial intersection of the intrinsic and extrinsic pathways. As a result, it plays a crucial role in the final common pathway of the cascade and has emerged as a key target in the research and development of new anticoagulants. A vital protease in the coagulation process called factor Xa is known to have some of its activity controlled by its interactions with sodium ions and factor Va.
Fibrin, the substance that forms the basis of all blood clots, is produced as a result of an intricate series of enzymatic reactions during blood coagulation. The intrinsic and extrinsic pathways, which make up this cascade's two arms, come together at factor Xa to form the common pathway. Prothrombin is activated by factor Xa to become thrombin, which then catalyzes the transformation of fibrinogen into fibrin.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V73140 | ARC19499 (BAX499) | 1350667-54-7 | ARC19499 is a nucleic acid aptamer that specifically binds to tissue factor pathway inhibitor (TFPI) and blocks the inhibitory effect of TFPI on factor Xa and TF/factor VIIa complexes. | |
V3489 | BMS-654457 | 1004551-41-0 | BMS-654457 is a novel, potent, reversible small-molecule inhibitor of factor XIa (FXIa), which binds to human and rabbit FXIa withKis of 0.2 and 0.42 nM, respectively. | |
V73150 | Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) | 65147-06-0 | Boc-Ile-Glu-Gly-Arg-AMC (IEGR-AMC) is an activating factor X (FXa)-specific fluorescent peptide substrate for the determination of factor VIII. | |
V73146 | CH3OCO-D-CHA-Gly-Arg-pNA acetate | 80895-10-9 | CH3OCO-D-CHA-Gly-Arg-pNA acetate is the chromogenic substrate of factor Xa. | |
V87433 | Ciraparantag acetate | 1644388-83-9 | Ciraparantag (PER977) acetate is a thrombin and Factor Xa inhibitor. | |
V79166 | D-Leu-Pro-Arg-Rh110-D-Pro | D-Leu-Pro-Arg-Rh110-D-Pro is a substrate of Factor Xa I (FXIa) with binding affinity. | ||
V85969 | D-Leu-Pro-Arg-Rh110-D-Pro acetate | |||
V79167 | D-Leu-Pro-Arg-Rh110-D-Pro TFA | D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate of Factor Xa I (FXIa) with binding affinity. | ||
V73135 | Dechloro Rivaroxaban | 1415566-28-7 | Dechloro Rivaroxaban is an orally bioactive, selective inhibitor of Factor Xa. | |
V73149 | Denecimig (Mim8) | 2488745-86-2 | Denecimig (Mim8) is an activated factor VIII mimetic human bispecific antibody with anti-FIXa and anti-FX arms that effectively stimulates FX activation, resulting in effective hemostasis in vitro and in vivo. | |
V71918 | Edoxaban impurity 4 (Edoxaban impurity D) | 480452-36-6 | Edoxaban impurity 4 is an impurity in Edoxaban. | |
V73143 | EMD 495235 | 811811-33-3 | EMD 495235 is a potent orally bioactive coagulation factor Xa (factor Xa) inhibitor (antagonist) with IC50 of 5.5 nM and a Ki of 6.8 nM. | |
V87429 | FaX-IN-1 | 503614-91-3 | FaX-IN-1 (compound 11A) is an intermediate for the preparation of FaX inhibitors and is used to study its inhibitory activity against venous thrombosis in rats. | |
V87432 | Fitusiran sodium | Fitusiran sodium is a small interfering RNA that specifically targets antithrombin (AT) messenger RNA to reduce AT production in the liver. | ||
V73148 | Frunexian (EP-7041) | 1803270-60-1 | Frunexian (EP-7041) is a selective factor XI/activated factor XI inhibitor targeting Factor XIa. | |
V73141 | FXa-IN-1 | 441328-10-5 | FXa-IN-1 is an FXa inhibitor (IC50= 3 nM, Ki: 0.7 nM) with considerable oral bioavailability (F) and half-life (in vivo). | |
V73144 | FXIa-IN-13 | 2629361-99-3 | FXIa-IN-13 (example 1) is a Factor Xa inhibitor (antagonist) with antithrombotic activity. | |
V84089 | FXIa-IN-14 | 2423992-72-5 | ||
V73151 | FXIa-IN-6 | 1551459-37-0 | FXIa-IN-6 is a potent inhibitor of FXIa, selective for most related serine proteases (Ki = 0.3 nM). | |
V73147 | FXIa-IN-7 | 2488952-56-1 | FXIa-IN-7 is an orally bioavailable and selective factor XIa inhibitor (antagonist) with IC50 of 0.4 nM. |